PMV Pharmaceuticals (PMVP) Retained Earnings (2019 - 2026)
PMV Pharmaceuticals' (PMVP) quarterly Retained Earnings came in at -$464.5 million in Q1 2026, down 553066.67% YoY from N/an in Q1 2025, and down 4.04% on a QoQ basis from -$446.5 million in Q4 2025.
PMV Pharmaceuticals (PMVP) Retained Earnings (2019 - 2026) Analysis & Trends
PMV Pharmaceuticals (PMVP) has 8 years of Retained Earnings data on file, last reported at -$464.5 million in Q1 2026.
- Quarterly Retained Earnings fell 553066.67% year-over-year to -$464.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$464.5 million (down 553066.67% YoY) and the FY2025 annual result came in at -$446.5 million, down 321289.93% from the prior year.
- Retained Earnings eased to -$464.5 million in Q1 2026, from -$446.5 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $410000.0 in Q3 2024 to a low of -$464.5 million in Q1 2026.
- A 5-year average of -$192.1 million and a median of -$241.0 million in 2022 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2024 — Retained Earnings jumped 100.14% — and 2026, when it tumbled 553066.67%.
- Tracing PMVP's Retained Earnings over 5 years: stood at -$241.0 million in 2022, then jumped by 100.09% to $224000.0 in 2023, then plunged by 37.95% to $139000.0 in 2024, then slumped by 321289.93% to -$446.5 million in 2025, then decreased by 4.04% to -$464.5 million in 2026.
- The last three Retained Earnings figures came in at -$464.5 million (Q1 2026), -$446.5 million (Q4 2025), and $91000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | PMV Pharmaceuticals | 70.74 Mn | -8.69 Mn | - | -482.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -464.49 Mn |
| Dec 31, 2025 | -446.45 Mn |
| Sep 30, 2025 | 91,000.00 |
| Jun 30, 2025 | -407.36 Mn |
| Mar 31, 2025 | 84,000.00 |
| Dec 31, 2024 | 139,000.00 |
| Sep 30, 2024 | 410,000.00 |
| Jun 30, 2024 | -326.49 Mn |
| Mar 31, 2024 | -325.27 Mn |
| Dec 31, 2023 | 224,000.00 |
| Sep 30, 2023 | -294.25 Mn |
| Jun 30, 2023 | -277.61 Mn |
| Mar 31, 2023 | -260.17 Mn |
| Dec 31, 2022 | -241.04 Mn |
| Sep 30, 2022 | -221.70 Mn |
| Jun 30, 2022 | -1.02 Mn |
| Mar 31, 2022 | -666,000.00 |
| Dec 31, 2021 | -167.73 Mn |
| Sep 30, 2021 | -149.37 Mn |
| Jun 30, 2021 | 7,000.00 |